Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) has improved outcomes and revolutionized disease management for patients with advanced stage disease [7]. This evidence concerns the gene BRAF and metastatic melanoma.